Best in Biotech 20 Dec 2023 Wrapping up 2023: A recap of top biotech moments of this year 2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023. December 20, 2023 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Dec 2023 Nine biotech companies to watch in 2024 2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024. December 19, 2023 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Opinion 18 Dec 2023 What to expect from biotech clinical trials in the coming year As cancer research has seen an increase in funding lately, here are some of the key clinical trends that you can expect in 2024. December 18, 2023 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Dec 2023 Seven companies shaping the future of precision medicine Explore the forefront of healthcare innovation with these seven cutting-edge biopharma companies specializing in precision medicine. December 14, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 4 Dec 2023 FDA CAR-T cell therapy warning: Are T cells malignant? Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […] December 4, 2023 - 4 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 23 Nov 2023 The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […] November 23, 2023 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2023 M&As: what’s up with the ADC buying spree? Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […] November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Opinion 1 Nov 2023 Could this be the start of a new era for PI3K drugs? There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […] November 1, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Podcast 27 Oct 2023Beyond Biotech podcast 69 – improving access to cell and gene therapy This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT), increasing access to these innovative treatments. Ori has developed a proprietary, full […] October 27, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 13 Oct 2023 How close are we to a cure for metastatic breast cancer? Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are in clinical trials, all with the hope of progressing toward U.S. Food and Drug Administration (FDA) approval. According to the World Health Organization (WHO), 2.3 […] October 13, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 13 Oct 2023Beyond Biotech podcast 67 – natural killer cells This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell […] October 13, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 12 Oct 2023 Can immunometabolism-based therapies transform the way cancers and autoimmune diseases are treated? The immune system protects our bodies from foreign invaders, but sometimes, when it malfunctions, it can result in life-threatening autoimmune disorders. But what if the immune system could be regulated to counter these diseases? Immunometabolism, an emerging field in therapeutics, aims to rein in autoimmunity altogether. According to Neil Weir, chief executive officer (CEO) of […] October 12, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email